Latest Kura Oncology News & Updates

See the latest news and media coverage for Kura. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kura Oncology (Kura)

Precision oncology therapeutics developer

kuraoncology.com

Headquarters: San Diego, United States
Founded year: 2014
Company type: Public company
Number of employees: 300–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Kura Oncology (Kura)

In short: Kura Oncology achieved FDA approval for Komzifti and reported strong clinical results across its renal cell carcinoma and leukemia programs.

Company announcements

July 27 Kura

Kura reports clinical activity of darlifarnib plus cabozantinib in ccRCC

Response rates up to 50% and median PFS of 13 months in cabozantinib-naïve patients. The combination was well tolerated. A randomized Phase 1b study is underway.

July 14 Kura

Kura announces long-term follow-up data for darlifarnib in RCC

Updated Phase 1a results from FIT-001 will be presented at KCRS 2026, showing enhanced VEGFR-targeted therapy potential.

June 11 Kura

Kura Oncology reports encouraging long-term results for ziftomenib in AML

The Phase 1/2 KOMET-007 trial showed high remission rates and 94% 12-month OS in NPM1-m AML patients.

June 3 Kura

Kura Oncology highlights darlifarnib as a foundation for KRAS-mutant cancers

Preliminary Phase 1a data show 67% ORR in pancreatic cancer, and a platform study is planned to start in early 2027.

Media coverage

July 27 Yahoo Finance

Kura Oncology Reports 50% Response Rate in RCC Combination Study

Kura Oncology (NASDAQ:KURA) presented updated results from its Phase 1 FIT-001 trial evaluating...

July 27 Yahoo Finance

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients...

July 15 The Globe and Mail

Kura Oncology Earnings Call Highlights Comzifty Launch

Kura Oncology’s latest earnings call struck an upbeat tone, as management spotlighted a swift U.S. launch for newly approved Comzifty, strong payer traction, and a...

July 14 The Globe and Mail

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

- Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET - SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) ...

Never miss news about Kura

Track Kura and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kura competitors & trending companies

Browse news for competitors to Kura and other trending companies.